Health Care·Pharmaceuticals·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-4.22 | N/A | -2525.29% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-4.22 | N/A | -2525.29% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced during the quarter. They emphasized the need for strategic adjustments but did not offer a clear outlook.
Management did not provide specific guidance for future quarters.
The company is focused on addressing current challenges.
The significant miss on EPS indicates that Prestige Consumer HE is facing substantial challenges, which may concern investors. The stock reacted slightly down by 0.16%, reflecting cautious sentiment in the market. Without guidance, investors may remain uncertain about the company's future performance and strategy.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BROADRIDGE FINL SOLU
May 11, 2009